Document:

Form of Stock Option Agreement under the Sagent Holding Co.

 Exhibit 10.16 
 SAGENT HOLDING CO. 
 2007 GLOBAL SHARE PLAN 

US SHARE OPTION AGREEMENT 
 Sagent Holding Co. (the “Company”) hereby grants you,                      (the
“Participant”), an option (the “Option”) under the Company’s 2007 Global Share Plan (the “Plan”) to purchase shares of Ordinary Shares (“Shares”) of the Company. Subject to the
provisions of the Plan and the Option Rules attached hereto as Exhibit A, the principal features of the Option are as follows: 
  

							
	Grant Number	  	  
	  	
	Date of Grant	  	  
	  	
	Vesting Commencement Date	  	  
	  	
	Exercise Price per Share	  	 $
	  	
	Number of Shares subject to the Option	  	  
	  	
	Type of Option:	  	  
	 	Incentive Stock Option (to the extent permitted by Applicable Law)
		  	  
	 	Nonstatutory Stock Option
	Expiration Date:	  	  
	  	

 Vesting Schedule 
 The Option shall become exercisable, in whole or in part, in accordance with the terms of the Plan, the Option Rules (attached hereto as Exhibit A) and the following vesting schedule:

 Twenty-five percent (25%) of the shares subject to each option shall vest on the first (1st) anniversary of the Vesting Commencement Date, and twenty-five
(25%) of the shares subject to the option shall vest on each subsequent anniversary of the Vesting Commencement Date. 

Option Termination: 
  

					
	 Event Triggering Option Termination
	  	Maximum Time to Exercise
After
Triggering Event*	 
	 Termination as Service Provider (except as provided below)
	  	 	3 months        	  
	 Termination as Service Provider due to Disability
	  	 	12 months        	  
	 Termination as Service Provider due to death
	  	 	12 months        	  

 *The Option may only
be exercised as to Shares that have vested as of the date of the Participant’s termination as a Service Provider and in no event may the Option be exercised after the Expiration Date. It is the Participant’s responsibility to exercise
the Option, if the Participant so desires, before it expires or terminates. 
 The Participant’s signature below
indicates his or her agreement, understanding, and acceptance that the Option is subject to all of the terms and conditions contained in Exhibit A and the Plan. Please be sure to read all of Exhibit A, which contains the
specific terms and conditions of the Option. 
 This US Share Option Agreement (the “Option Agreement”)
does not represent a securities interest in the Company, which interest may accrue only upon the exercise of the Option in accordance with its terms. 
  

					
	SAGENT HOLDING CO.	  		  	PARTICIPANT
			
	  
	  		  	  

	Ronald Pauli, Chief Financial Officer	  		  	[Name of Participant]
	  
	  		  	  

	Date	  		  	Date

 EXHIBIT A 

OPTION RULES 
 1. Grant of Option. The Administrator hereby grants to the Participant under the Plan the right to purchase the number of Shares set forth on the first page of this Option Agreement (the
“Grant Notice”), at the Exercise Price per Share set forth in the Grant Notice, and subject to all of the terms and conditions in this Option Agreement and the Plan, a copy of which the Participant acknowledges having received.
Unless otherwise defined herein, the capitalized terms in this Option Agreement shall have the meanings ascribed to those terms in the Plan. In the event of a conflict between the terms and conditions of the Plan and this Option Agreement, the terms
and conditions of the Plan shall prevail unless otherwise indicated. 
 The aggregate Fair Market Value (determined with respect
to each Incentive Stock Option at the time the Incentive Stock Option is granted) of Shares with respect to which Incentive Stock Options are exercisable for the first time by the Participant during any calendar year (under the Plan or any other
plan of the Company) shall not exceed US$100,000. If the Option is designated in the Grant Notice as an Incentive Stock Option, all or a portion of the Option may nonetheless be treated as a Nonstatutory Stock Option in accordance with
Section 6(b) of the Plan. 
 2. Exercise of Option. 

(a) Right to Exercise. The Option shall be exercisable during its term cumulatively according to the Vesting Schedule set out in
the Grant Notice and with the applicable provisions of the Plan. Notwithstanding the foregoing, the Option may not be exercised for a fraction of a Share. 
 (b) Method of Exercise. The Option shall be exercisable to the extent then vested by delivery of a written exercise notice in the form attached hereto as Exhibit B (the
“Exercise Notice”) or in a manner and pursuant to such procedures as the Administrator may determine, which shall state the election to exercise the Option, the number of Shares with respect to which the Option is being exercised,
and such other representations and agreements as may be required by the Company. The Exercise Notice shall be signed by the Participant (or by the Participant’s beneficiary or other person entitled under the Plan to exercise the Option in the
event of the Participant’s death) and shall be delivered in person or by certified mail to the Company. The Exercise Notice shall be accompanied by payment of the aggregate Exercise Price as to all Shares exercised together with any applicable
tax withholding. The Option shall be deemed to be exercised as of the date (the “Exercise Date”) (i) the Company receives (as determined by the Administrator in its sole, but reasonable, discretion) the fully executed Exercise
Notice accompanied by payment of the aggregate Exercise Price, together with any applicable tax withholding, and (ii) all other applicable terms and conditions of the Option Agreement are satisfied. 

No Shares will be issued pursuant to the exercise of an Option unless such issuance and such exercise comply with Applicable Laws.
Assuming such compliance, for income tax purposes the Shares will be considered transferred to the Participant on the date on which the Option is exercised with respect to such Shares. 

 (c) Approval by Members and Compliance Restrictions on Exercise. Any other provision
of this Agreement to the contrary notwithstanding, no portion of the Option shall be exercisable at any time prior to the approval of the Plan by the Members of the Company. No Shares shall be issued pursuant to the exercise of an Option, unless the
issuance and exercise, including the form of consideration used to pay the Exercise Price, comply with Applicable Law. 
 (d)
Issuance of Shares. After receiving the Exercise Notice, the Company shall cause to be issued a certificate or certificates for the Shares as to which the Option has been exercised, registered in the name of the person exercising this Option
(or in the names of such person and his or her spouse as community property or as joint tenants with right of survivorship). The Company shall cause the certificate or certificates to be deposited in escrow or delivered to or upon the order of the
person exercising the Option. 
 3. Participant’s Representations. In the event the Shares have not been registered
under the Securities Act on the Exercise Date, the Participant shall, if required by the Company, concurrently with the exercise of all or any portion of the Option, deliver to the Company his or her Investment Representation Statement in the form
attached hereto as Exhibit C, as well as any other representations necessary or appropriate, in the judgment of the Administrator, to comply with Applicable Law. 
 4. Market Stand-Off. 
 (a) The Participant agrees that the Participant shall
not directly or indirectly sell, make any short sale of, loan, hypothecate, pledge, offer, grant or sell any option or other contract for the purchase of, purchase any option or other contract for the sale of, or otherwise dispose of or transfer, or
agree to engage in any of the foregoing transactions with respect to, any Shares acquired under the Option Agreement for a period specified by the Company or its underwriters. Such restriction (the “Market Stand-Off”) shall be in
effect for such period of time commencing on and following the effective date of the first Qualified Public Offering as may be requested by the Company or its underwriters. In no event, however, shall the Market Stand-Off period exceed 180 days
following the effective date of the first Qualified Public Offering. In the event of the declaration of a share dividend, a spin-off, a share split, an adjustment in conversion ratio, a recapitalization or a similar transaction affecting the
Company’s outstanding securities without receipt of consideration, any new, substituted or additional securities that are by reason of such transaction distributed with respect to any Shares subject to the Market Stand-Off, or into which such
Shares thereby become convertible, shall immediately be subject to the Market Stand-Off. In order to enforce the Market Stand-Off, the Company may impose stop-transfer instructions with respect to the Shares acquired under this Option Agreement
until the end of the applicable Market Stand-Off period. The Company’s underwriters shall be beneficiaries of the agreement set forth in this Section 4, and the Participant agrees that any transferee of any Participant shall be bound by
the provisions of this Section 4. This Section 4 shall not apply to Shares registered in the first Qualified Public Offering. 

  
 -2-

 (b) For purposes of this Section 4, a “Qualified Public Offering”
shall mean the closing of an underwritten public offering, pursuant to an effective registration statement under the Securities Act or pursuant to a valid qualification or filing under Applicable Law of another jurisdiction, of the Shares or other
equity securities of the Company. Notwithstanding the foregoing, a Qualified Public Offering shall not include a registration relating solely to employee benefit plans or to a Rule 145 transaction under the Securities Act or to similar
registrations under Applicable Law of another jurisdiction. 
 (c) The Participant agrees to execute and deliver such other
agreements as may be reasonably requested by the Company or its underwriters which are consistent with the foregoing or which are necessary to give further effect thereto. In addition, if requested by the Company or the representative of the
underwriters of Shares (or other securities) of the Company, the Participant shall provide, within ten (10) days of such request, such information as may be required by the Company or such representative in connection with the completion of any
public offering of the Company’s securities pursuant to a registration statement filed under the Securities Act. The obligations described in this Section 4 shall not apply to a registration relating solely to employee benefit plans on
Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a Commission Rule 145 transaction on Form S-4 or similar forms that may be promulgated in the future. The Company may impose
stop-transfer instructions with respect to the Shares (or other securities) subject to the foregoing restriction until the end of said one hundred eighty (180) day (or other) period. The Participant agrees that any transferee of the Option or
shares acquired pursuant to the Option shall be bound by this Section 4. 
 5. Method of Payment. Payment of the
aggregate Exercise Price shall be by any of the following forms of consideration, or a combination thereof, at the election of the Participant: 
 (a) cash or check; 
 (b) at the discretion of the Administrator, consideration
received by the Company under a formal cashless exercise program adopted by the Company in connection with the Plan; or 
 (c)
at the discretion of the Administrator, surrender of other Shares which, if accepted by the Company, would not subject the Company to adverse accounting as determined by the Administrator. 

6. Non-Transferability of Option. The Option and the rights and privileges conferred hereby shall not be sold, pledged or
otherwise transferred (whether by operation of law or otherwise) in any manner otherwise than (i) by will or (ii) by the laws of descent and distribution, shall not be subject to sale under execution, attachment, levy or similar process
and may be exercised during the lifetime of the Participant only by the Participant. The terms of the Plan and the Option Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of the Participant. 

  
 -3-

 7. Term of Option. The Option shall in any event expire on the expiration date set
forth in the Grant Notice, and may be exercised prior to the expiration date only in accordance with the Plan and the terms of this Option Agreement. 
 8. Tax Obligations. 
 (a) Tax Withholding. The Participant shall make
appropriate arrangements with the Company (or the Parent or Subsidiary employing or retaining the Participant) for the satisfaction of all US Federal, state, local and non-US income and employment tax withholding requirements applicable to the
Option exercise. The Participant hereby acknowledges, understands and agrees that the Company may refuse to honor the exercise and refuse to deliver Shares if the withholding amounts are not delivered at the time of exercise. 

(b) Notice of Disqualifying Disposition of Shares. If the Option granted to the Participant herein is designated as an Incentive
Stock Option, and if the Participant sells or otherwise disposes of any of the Shares acquired pursuant to the Incentive Stock Option on or before the later of (1) the date two years after the Date of Grant and (2) the date one year after
the date of exercise, the Participant shall immediately notify the Company in writing of such disposition. The Participant hereby acknowledges and agrees that the Participant may be subject to tax withholding by the Company on the compensation
income recognized by the Participant in connection with the exercise of the Option. 
 (c) Code Section 409A. Under
Code Section 409A, an Option that vests after December 31, 2004 that was granted with a per Share exercise price that is determined by the Internal Revenue Service (the “IRS”) to be less than the fair market value of a
Share on the date of grant (a “discount option”) may be considered “deferred compensation”. An Option that is a “discount option” may result in (i) income recognition by the Participant prior to the exercise of the
Option, (ii) an additional twenty percent (20%) tax, and (iii) potential penalty and interest charges. The Participant acknowledges that the Company cannot and has not guaranteed that the IRS will agree that the per Share exercise
price of this Option equals or exceeds the fair market value of a Share on the date of grant in a later examination. The Participant agrees that if the IRS determines that the Option was granted with a per Share exercise price that was less than the
fair market value of a Share on the date of grant, the Participant will be solely responsible for the Participant’s costs related to such a determination. 
 9. Adjustment of Shares. In the event of any transaction described in Section 12 of the Plan, the terms of the Option (including, without limitation, the number and kind of the Shares subject
to the Option and the Exercise Price) may be adjusted as set forth in Section 12 of the Plan. This Option Agreement shall in no way affect the right of the Company to adjust, reclassify, reorganize or otherwise change its capital or business
structure or to merge, consolidate, dissolve, liquidate or sell or transfer any part of its business or assets. 
 10.
Legality of Initial Issuance. No Shares shall be issued upon the exercise of the Option unless and until the Company has determined that: (i) the Company and the Participant have taken all actions required to register the Shares under
the Securities Act or to perfect an exemption from the registration requirements thereof, if applicable; (ii) all applicable listing requirements of any stock exchange or other securities market on which the Shares are listed have been
satisfied; and (iii) all other applicable provisions of state or US federal law or other Applicable Law have been satisfied. 

  
 -4-

 11. No Registration Rights. The Company may, but shall not be obligated to, register
or qualify the sale of Shares under the Securities Act or any other Applicable Law. The Company shall not be obligated to take any affirmative action in order to cause the sale of Shares under this Option Agreement to comply with any Applicable Law.

 12. Securities Law Restrictions. Regardless of whether the offering and sale of Shares under the Plan have been
registered under the Securities Act or have been registered or qualified under the securities laws of any state, the Company at its discretion may impose restrictions upon the sale, pledge or other transfer of the Shares (including the placement of
appropriate legends on share certificates or the imposition of stop-transfer instructions) if, in the judgment of the Company, such restrictions are necessary or desirable in order to achieve compliance with the Securities Act, the securities laws
of any state or any other Applicable Law. 
 13. Acknowledgement. The Participant acknowledges receipt of a copy of the
Plan and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts this Option subject to all of the terms and provisions thereof. The Participant has reviewed the Plan and this Option in their entirety, has had
an opportunity to obtain the advice of counsel prior to executing this Option and fully understands all provisions of the Option. The Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the
Administrator upon any questions arising under the Plan or this Option. The Participant further agrees to notify the Company upon any change in the residence address indicated below. 

14. General Provisions. 
 (a) Notice. Any notice required by the terms of this Option Agreement shall be given in writing and shall be deemed effective upon personal delivery or upon deposit with the United States Postal
Service, by registered or certified mail, with postage and fees prepaid. Notice shall be addressed to the Company at its principal executive office and to the Participant at the address that he or she most recently provided to the Company.

 (b) Successors and Assigns. Except as provided herein to the contrary, this Option Agreement shall be binding upon and
inure to the benefit of the parties to this Option Agreement, their respective successors and permitted assigns. 
 (c) No
Assignment. Except as otherwise provided in this Option Agreement, the Participant shall not assign any of his or her rights under this Option Agreement without the prior written consent of the Company, which consent may be withheld in its sole
discretion. The Company shall be permitted to assign its rights or obligations under this Option Agreement, but no such assignment shall release the Company of any obligations pursuant to this Option Agreement. 

(d) Severability. The validity, legality or enforceability of the remainder of this Option Agreement shall not be affected even if
one or more of the provisions of this Option Agreement shall be held to be invalid, illegal or unenforceable in any respect. 

  
 -5-

 (e) Administration. Any determination by the Administrator in connection with any
question or issue arising under the Plan or this Option Agreement shall be final, conclusive, and binding on the Participant, the Company, and all other persons. 
 (f) Headings. The section headings in this Option Agreement are inserted only as a matter of convenience, and in no way define, limit or interpret the scope of this Option Agreement or of any
particular section. 
 (g) Counterparts. This Option Agreement may be executed simultaneously in two or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 (h) Entire Option Agreement; Governing Law. The provisions of the Plan are incorporated herein by reference. The Plan and this Option Agreement constitute the entire agreement of the parties with
respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Participant with respect to the subject matter hereof, and may not be modified adversely to the Participant’s
interest except by means of a writing signed by the Company and the Participant. This Option Agreement is governed by the laws of the State of California applicable to contracts executed in and to be performed in that State, except with respect to
its choice of law rules. 
 15. No Guarantee of Continued Service. THE PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE
VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY OR THE AFFILIATE EMPLOYING THE PARTICIPANT (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THE OPTION OR
ACQUIRING SHARES HEREUNDER). THE PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS OPTION AGREEMENT, THE OPTION GRANTED HEREUNDER, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR
IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH THE PARTICIPANT’S RIGHT OR THE RIGHT OF THE COMPANY (OR THE AFFILIATE EMPLOYING THE
PARTICIPANT) TO TERMINATE THE PARTICIPANT’S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE. 

  
 -6-

 EXHIBIT B 

SAGENT HOLDING CO. 
 2007 GLOBAL SHARE PLAN 
 EXERCISE NOTICE 

Sagent Holding Co. 
 Attention: Secretary

 1. Exercise of Option. Effective as of today,
                    ,
                    , the undersigned (the “Participant”) hereby elects to exercise the Participant’s option to purchase
             shares of Ordinary Shares (the “Shares”) of Sagent Holding Co. (the “Company”), under and pursuant to the 2007 Global Share Plan (the
“Plan”) and the US Share Option Agreement dated                     ,
             (the “Option Agreement”). Unless otherwise defined herein, the capitalized terms in this notice of exercise (the “Exercise Notice”)
shall have the meanings ascribed to those terms in the Plan. 
 2. Delivery of Payment. The Participant herewith delivers
to the Company the full Exercise Price of the Shares with respect to which the Participant is exercising the Option, and any and all withholding taxes due in connection with the exercise of the Option. 

3. Representations of the Participant. The Participant hereby acknowledges that the Participant has received and read, and
understands the Plan and the Option Agreement, including the Option Rules, and agrees to abide by and be bound by their terms and conditions. 
 4. Rights as Member. Until the issuance of the Shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or
receive dividends or any other rights as a Member shall exist with respect to the Shares subject to the Option, notwithstanding the exercise of the Option. The Shares shall be issued to the Participant as soon as practicable after the Option is
exercised in accordance with the Option Agreement. No adjustment shall be made for a dividend or other right for which the record date is prior to the date of issuance except as provided in Section 12 of the Plan. 

5. Right of First Refusal. 
 (a) Transfer Notice. If at any time the Participant proposes to sell, transfer, assign, encumber, pledge, hypothecate or otherwise dispose of in any way (each, a “Transfer”) all or
any part of or any interest in the Shares to one or more third parties pursuant to an understanding with the third parties, then the Participant (a “Selling Participant”) shall first give the Company written notice of the Selling
Participant’s intention to make the Transfer (the “Transfer Notice”), which Transfer Notice shall include (i) a description of the Shares to be transferred (the “Offered Shares”), (ii) the identity of
the prospective transferee(s), (iii) a certification as to the number of Shares currently owned, directly or indirectly, by the proposed transferee and its Affiliates and (iv) the consideration and the material terms and conditions upon

 
which the proposed Transfer is to be made. For purposes of this Section 5, “Affiliate” shall mean any person or entity that directly, or indirectly through one or more
intermediaries, controls, or is controlled by, or is under common control with such entity. The Transfer Notice shall certify that the Selling Participant has received a firm offer from the prospective transferee(s) and in good faith believes a
binding agreement for the Transfer is obtainable on the terms set forth in the Transfer Notice. The Transfer Notice shall also include a copy of any written proposal, term sheet or letter of intent or other agreement relating to the proposed
Transfer and proof satisfactory to the Company that the proposed Transfer will not violate any Applicable Law. 
 (b)
Company’s Option. The Company and its assignee(s) shall have an option for a period of thirty (30) days from receipt of the Transfer Notice to elect to purchase the Offered Shares at the same price and subject to the same material
terms and conditions as described in the Transfer Notice. The Company and its assignee(s) may exercise such purchase option and, thereby, purchase all (or a portion of) the Offered Shares by notifying the Selling Participant in writing before
expiration of such thirty (30)-day period as to the number of Offered Shares that it wishes to purchase. If the Company or an assignee gives the Selling Participant notice that it desires to purchase the Offered Shares, then payment for the Offered
Shares shall be by check or wire transfer, against delivery of the Offered Shares to be purchased at a place agreed upon between the parties and at the time of the scheduled closing therefor, which shall be no later than thirty (30) days after
the Company’s receipt of the Transfer Notice, unless the Transfer Notice contemplates a later closing with the prospective third party transferee(s) or unless the value of the purchase price has not yet been established pursuant to
Section 5(c) hereof. 
 (c) Valuation of Property. Should the purchase price specified in any Transfer Notice be
payable in property other than cash or evidences of indebtedness, the Company and its assignee(s) shall have the right to pay the purchase price in the form of cash equal in amount to the value of such property. If the Selling Participant and the
Company or its assignee(s) cannot agree on such cash value within ten (10) days after the Company’s receipt of the Transfer Notice, the valuation shall be as determined in good faith by the Administrator. If the time for the closing of the
purchase has expired but for the determination of the value of the purchase price offered by the prospective transferee(s), then such closing shall be held on or prior to the fifth (5th) business day after the valuation shall have been made
pursuant to this Section 5(c). 
 (d) Non-Exercise of Right. To the extent that any Offered Share has not been
purchased pursuant to Section 5(b) hereof and the Company has determined that the proposed Transfer of the unpurchased Offered Shares to the third party transferee identified in the Transfer Notices would not constitute a Change in Control, the
Company shall promptly so notify the Selling Participant and the Selling Participant shall have a period of thirty (30) days from receipt of such notice in which to sell such unpurchased Offered Shares upon terms and conditions (including the
purchase price) no more favorable than those specified in the Transfer Notice; provided, however, that the transferee shall agree in writing on a form prescribed by the Company to be bound by all provisions of this Exercise Notice. In
the event that the Selling Participant does not consummate such sale or disposition within such thirty (30) day period, all rights of first refusal under this Section 5 shall continue to be applicable to any subsequent

  
 -2-

 
disposition of the Offered Shares by the Selling Participant until such rights lapse in accordance with the terms of this Section 5. Furthermore, the exercise or nonexercise of such rights
shall not adversely affect the right of the Company and its assignee(s) to make subsequent purchases from the Selling Participant of Shares. 
 (e) Additional Shares or Substituted Securities. In the event of the declaration of a share dividend, the declaration of an extraordinary dividend payable in a form other than shares, a spin-off, a
share split, an adjustment in conversion ratio, a recapitalization or a similar transaction affecting the Company’s outstanding securities without receipt of consideration, any new, substituted or additional securities or other property
(including money paid other than as an ordinary cash dividend) that are by reason of such transaction distributed with respect to any Shares subject to this Section 5 or into which such Shares thereby become convertible shall immediately be
subject to this Section 5. Appropriate adjustments to reflect the distribution of such securities or property shall be made to the number and/or class of Shares subject to this Section 5. 

(f) Exception for Certain Family Transfers. Anything to the contrary contained in this Section 5 notwithstanding, the
transfer of any or all of the Shares during the Participant’s lifetime or on the Participant’s death by will or intestacy to the Participant’s immediate family or a trust for the benefit of the Participant’s immediate family
shall be exempt from the provisions of this Section 5. “Immediate Family” as used herein shall mean spouse, lineal descendant or antecedent, father, mother, brother or sister. In such case, the transferee or other recipient shall
receive and hold the Shares so transferred subject to the provisions of this Section 5, and there shall be no further transfer of such Shares except in accordance with the terms of this Section 5. 

(g) Change in Control. In the event of a Change in Control, all rights of first refusal under this Section 5 shall remain in
full force and effect and shall apply to the new shares of capital received in exchange for the Shares in consummation of the Change in Control, but only to the extent the Shares are at the time covered by the rights of first refusal under this
Section 5. 
 (h) Lapse. Notwithstanding any other provision of this Section 5, any right of first refusal
provided in this Section 5 shall terminate as to any Shares upon the earlier to occur of (i) a Qualified Public Offering, or (ii) a Change in Control in which the successor corporation has equity securities that are publicly traded.

 6. Tax Consultation. The Participant hereby acknowledges that he or she understands that the Participant may suffer
adverse tax consequences as a result of the Participant’s purchase or disposition of the Shares. The Participant hereby represents that the Participant has consulted with any tax consultants the Participant deems advisable in connection with
the purchase or disposition of the Shares and that the Participant is not relying on the Company for any tax advice. 

  
 -3-

 7. Restrictions on Transfer. 

(a) Legends. The Participant hereby acknowledges, understands and agrees that the Company may cause the legends set forth below or
legends substantially equivalent thereto, to be placed upon any certificate(s) evidencing ownership of the Shares together with any other legends that may be required by the Company or by state or US federal securities laws or other Applicable Law:

 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, (THE
“ACT”) OR QUALIFIED OR REGISTERED UNDER STATE SECURITIES OR BLUE SKY LAWS. THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION, AND NEITHER THESE SECURITIES NOR ANY INTEREST OR PARTICIPATION
THEREIN MAY BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR DISPOSED OF EXCEPT IN COMPLIANCE WITH THE ACT, APPLICABLE STATE SECURITIES OR BLUE SKY LAWS AND THE APPLICABLE RULES AND REGULATIONS THEREUNDER. THE ISSUER OF
THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AND A RIGHT OF FIRST REFUSAL HELD BY THE
ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN THE EXERCISE NOTICE BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SECURITIES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH TRANSFER RESTRICTIONS AND RIGHT OF FIRST
REFUSAL ARE BINDING ON TRANSFEREES OF THESE SECURITIES. 
 THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO
RESTRICTIONS ON TRANSFER FOR A PERIOD FOLLOWING THE EFFECTIVE DATE OF THE UNDERWRITTEN PUBLIC OFFERING OF THE COMPANY’S SECURITIES AS SET FORTH IN AN AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SECURITIES AND MAY NOT BE SOLD
OR OTHERWISE DISPOSED OF BY THE HOLDER WITHOUT THE CONSENT OF THE ISSUER OR THE MANAGING UNDERWRITER. 
 (b) Stop-Transfer
Notices. The Participant agrees that, in order to ensure compliance with the restrictions referred to herein, the Company may issue appropriate “stop transfer” instructions to its transfer agent, if any, and that, if the Company
transfers its own securities, it may make appropriate notations to the same effect in its own records. 

  
 -4-

 (c) Rights of the Company. The Company shall not (i) record on its books the
transfer of any Shares that have been sold or transferred in contravention of this Exercise Notice or (ii) treat as the owner of Shares, or otherwise to accord voting, dividend or liquidation rights to, any transferee to whom Shares have been
transferred in contravention of this Exercise Notice. Any Transfer of Shares not made in conformance with this Exercise Notice shall be null and void and shall not be recognized by the Company. 

(d) Removal of Legends. If, in the opinion of the Company and its counsel, any legend placed on a certificate of shares
representing Shares sold under this Exercise Notice is no longer required, the holder of the certificate shall be entitled to exchange the certificate for a certificate representing the same number of Shares but without such legend. 

8. Successors and Assigns. The Company may assign any of its rights under this Exercise Notice to single or multiple assignees,
and the terms and conditions of this Exercise Notice shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth, the terms and conditions of this Exercise Notice shall be binding
upon the Participant and his or her heirs, executors, administrators, successors and assigns. 
 9. Interpretation. Any
dispute regarding the interpretation of this Exercise Notice shall be submitted by the Participant or by the Company forthwith to the Administrator, which shall review such dispute at its next regular meeting. The resolution of such a dispute by the
Administrator shall be final and binding on all parties. 
 10. Governing Law; Severability. This Exercise Notice is
governed by the laws of the State of California applicable to contracts executed in and to be performed in that State without giving effect to its choice of law rules. 
 11. Entire Agreement. The Plan and Option Agreement are incorporated herein by reference. This Exercise Notice, the Plan, the Option Agreement and the Investment Representation Statement constitute
the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Participant with respect to the subject matter hereof, and may not be modified
adversely to the Participant’s interest except by means of a writing signed by the Company and the Participant. 

[SIGNATURE PAGE FOLLOWS] 

  
 -5-

 IN WITNESS WHEREOF, this Exercise Notice is deemed made as of the date first set forth
above. 
  

					
	Submitted by:	 		  	Accepted by:
			
	PARTICIPANT	 		  	SAGENT HOLDING CO.
			
	  
	 		  	  

	Signature	 		  	By
			
	  
	 		  	  

	Print Name	 		  	Title
			
	Address:	 		  	
			
	  
	 		  	
	  
	 		  	
	  
	 		  	
			
		 		  	  

		 		  	Date Received

 SIGNATURE PAGE TO
EXERCISE NOTICE 

 EXHIBIT C 

INVESTMENT REPRESENTATION STATEMENT 
  

					
	PARTICIPANT:	  	  
	  	
			
	COMPANY:	  	SAGENT HOLDING CO.	  	
			
	SECURITIES:	  	ORDINARY SHARES	  	
			
	AMOUNT:	  	  
	  	
			
	DATE:	  	  
	  	

 In connection with the purchase of the above-listed Securities, the Participant represents to the
Company the following: 
 (a) The Participant hereby acknowledges that the Participant is aware of the Company’s business
affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the Securities. The Participant is acquiring these Securities for investment for the
Participant’s own account only and not with a view to, or for resale in connection with, any “distribution” thereof within the meaning of the Securities Act of 1933, as amended (the “Securities Act”). 

(b) The Participant hereby acknowledges and understands that the Securities constitute “restricted securities” under the
Securities Act and have not been registered under the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Participant’s investment intent as expressed
herein. In this connection, the Participant understands that, in the view of the Securities and Exchange Commission, the statutory basis for such exemption may be unavailable if the Participant’s representation was predicated solely upon a
present intention to hold these Securities for the minimum capital gains period specified under tax statutes, for a deferred sale, for or until an increase or decrease in the market price of the Securities, or for a period of one year or any other
fixed period in the future. The Participant further understands that the Securities must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such registration is available. The Participant
further acknowledges and understands that the Company is under no obligation to register the Securities. The Participant understands that the certificate evidencing the Securities will be imprinted with a legend that prohibits the transfer of the
Securities unless they are registered or such registration is not required in the opinion of counsel satisfactory to the Company, and with any other legend required under applicable state securities laws. 

(c) The Participant hereby acknowledges that the Participant is familiar with the provisions of Rule 701 and Rule 144, each
promulgated under the Securities Act, which, in substance, permit limited public resale of “restricted securities” acquired, directly or indirectly from the issuer thereof, in a non-public offering subject to the satisfaction of certain
conditions. Rule 701 provides that if the issuer qualifies under Rule 701 at the time of the grant of the option 

 
to the Participant, the exercise will be exempt from registration under the Securities Act. In the event the Company becomes subject to the reporting requirements of Section 13 or 15(d) of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), ninety (90) days thereafter (or such longer period as any market stand-off agreement may require) the Securities exempt under Rule 701 may be resold,
subject to the satisfaction of certain of the conditions specified by Rule 144, including: (1) the resale being made through a broker in an unsolicited “broker’s transaction” or in transactions directly with a market maker
(as this term is defined under the Exchange Act); and, in the case of an affiliate, (2) the availability of certain public information about the Company, (3) the amount of Securities being sold during any three month period not exceeding
the limitations specified in Rule 144(e), and (4) the timely filing of a Form 144, if applicable. 
 In the event that
the Company does not qualify under Rule 701 at the time of grant of the Option, then the Securities may be resold in certain limited circumstances subject to the provisions of Rule 144, which requires the resale to occur not less than one
year after the later of the date the Securities were sold by the Company or the date the Securities were sold by an affiliate of the Company, within the meaning of Rule 144; and, in the case of acquisition of the Securities by an affiliate, or
by a non-affiliate who subsequently holds the Securities less than two years, the satisfaction of the conditions set forth in sections (1), (2), (3) and (4) of the paragraph immediately above. 

(d) The Participant further understands that in the event all of the applicable requirements of Rule 701 or 144 are not satisfied,
registration under the Securities Act, compliance with Regulation A, or some other registration exemption will be required; and that, notwithstanding the fact that Rules 144 and 701 are not exclusive, the Staff of the Securities and Exchange
Commission has expressed its opinion that persons proposing to sell private placement securities other than in a registered offering and otherwise than pursuant to Rules 144 or 701 will have a substantial burden of proof in establishing that an
exemption from registration is available for such offers or sales, and that such persons and their respective brokers who participate in such transactions do so at their own risk. The Participant understands that no assurances can be given that any
such other registration exemption will be available in such event. 
  

	
	Signature of the Participant:
	
	  

	
	Date:
                                

  
 -2-Manufacture and Supply Agreement, dated as of December 17, 2007

 Exhibit 10.18 
 MANUFACTURE AND SUPPLY AGREEMENT 
 This Manufacture and Supply
Agreement (this “Agreement”) is made and entered into as of December 17, 2007 (the “Effective Date”) by and among A.C.S. Dobfar S.p.a., an Italian corporation, having its principal place of business at Viale
Addetta, 4/12 Tribiano 20067 Milan Italy (“DOBFAR” or “SUPPLIER”), WorldGen LLC, a New Jersey Limited Liability Company, having its principal place of business at 120 Route 17 North P.O. Box 1579 Paramus, NJ 07653
USA (“WORLDGEN”), and SAGENT PHARMACEUTICALS, INC., a Wyoming corporation, having its principal place of business at 1901 N. Roselle Road, Schaumburg, IL 60195 (“SAGENT”). 

WHEREAS, DOBFAR develops, manufactures and supplies a broad range of prescription pharmaceutical products and possesses the necessary
expertise to develop, manufacturer and supply the products as described on Exhibit A hereto; 
 WHEREAS, DOBFAR has
submitted or is preparing, and intends to submit, an abbreviated new drug application for the product (“ANDA”); 
 WHEREAS, DOBFAR and SAGENT both desire to enter into a commercial relationship wherein DOBFAR will (i) provide the Services (as hereinafter defined) as set forth in this Agreement, (ii) supply
the Product in finished form, via WORLDGEN, to SAGENT and, (iii) appoint SAGENT as a non-exclusive distributor of the Product in the Territory pursuant to the terms and conditions set forth herein; 

WHEREAS, WORLDGEN is SUPPLIER’S United States distributor who will manage and sell the supply of the products to SAGENT on behalf of
DOBFAR; and 
 WHEREAS, DOBFAR, SAGENT and WORLDGEN (collectively, the “Parties”, and each individually, a
“Party”) desire to establish in this Agreement the terms upon which DOBFAR will, upon approval of the ANDA, manufacture and supply product that is consistent in all respects with the Specifications (the “Product”)
for sale by SAGENT via WORLDGEN in the Territory. 
 NOW, THEREFORE, in consideration of the terms, conditions and mutual
covenants set forth in this Agreement and other good and valuable consideration hereinafter set forth, the Parties agree as follows: 
 ARTICLE 1 
 DEFINITIONS 

As used in this Agreement, the following words and phrases shall have the following meanings and grammatical variations thereof shall
have corresponding meanings (the singular shall be interpreted as including the plural and vice versa, unless the context clearly indicates otherwise): 
 1.1 “Act” means the United States Food Drug and Cosmetic Act, as amended, and includes the rules and regulations promulgated thereunder. 

1.2 “Agreement” shall have the meaning assigned to such term in the introductory paragraph. 

 1.3 “Affiliate” means with respect to any Party hereto, any entity which
indirectly or directly through stock ownership or through other arrangements either controls, or is controlled by or is under common control with, such Party. 
 1.4 “ANDA” shall have the meaning set forth in the recitals. 

1.5 “API” means the active pharmaceutical ingredient of the Product. 

1.6 “Applicable Laws” means all laws, statutes and regulations of any Governmental Authority having jurisdiction over
the manufacturing, use, marketing or sale of the Product, as the same may be amended from time to time. 
 1.7 “Approval
Date” means the date that DOBFAR receives the FDA’s written approval of the ANDA. 
 1.8 “Batch”
shall be as defined in the current Specifications. 
 1.9 “Certificate of Analysis” means the certificate for
each Batch of Product delivered. 
 1.10 “cGMP” means shall mean current Good Manufacturing Practice as set
forth in the Act and applicable regulations promulgated thereunder by the FDA as may be amended from time to time, as well as current good manufacturing practices applicable to a Product or the making thereof at the Manufacturing Facility, set forth
by any Governmental Authority. 
 1.11 “Commercial Launch Date” shall mean the date on which SAGENT makes a Product
available for full-scale commercial sale, prior to which date SAGENT shall have received such Product from DOBFAR/WORLDGEN in such quantities as SAGENT shall reasonably require in order to ensure inventory levels sufficient to meet SAGENT’s
customers requirements. 
 1.12 “Confidential Information” shall have the meaning set forth in
Section 12.1. 
 1.13 “Costs” shall have the meaning set forth in Section 11.1. 

1.14 “Disclosing Party” shall have the meaning set forth in Section 12.1. 

1.15 “Effective Date” shall have the meaning assigned to such term in the introductory paragraph. 

1.16 “FDA” means the United States Food and Drug Administration, or any successor entity thereto. 

1.17 “Governmental Authority” means any governmental department, commission, board, bureau, agency, court or other
instrumentality of the United States or any other supranational organization of sovereign states, including without limitation, the European Union. 
 1.18 “Net Margin” means, for any calendar quarter, the Net Sales of the Product during such quarter less the aggregate of the Transfer Prices paid for such Product. 

1.19 “Indemnitee” shall have the meaning set forth in Section 11.3. 

1.20 “Indemnitor” shall have the meaning set forth in Section 11.3. 

  
 2 

 CONFIDENTIAL TREATMENT 
 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. This text has been separately filed with the Securities and Exchange Commission 

 
 1.21 “Initial Term” shall have the meaning
set forth in Section 2.1. 
 1.22 “Launch Date” means the date designated by agreement of the Parties as
the first date on which the Product may be made available for sale in the Territory. 
 1.23 “Transfer Price”
means [***] as set forth on Exhibit C attached hereto. 
 1.24 “Manufacturing Facility” means Suppliers’
or its affiliates’ Manufacturing facilities located at [***] or any other manufacturing facility approved in writing by SAGENT and at which DOBFAR represents to SAGENT it will be able to manufacture the Product in accordance with all Applicable
Laws, cGMP and the Specifications applicable to such Product. 
 1.25 “NDC” means National Drug Code.

 1.26 “Net Sales” means, for each calendar quarter, a value equal to SAGENT’s gross invoiced sales of
the Product to its customers for such calendar quarter minus the following deductions from such gross invoiced amount which are actually incurred, allowed or specifically allocated to the Product, including, without limitation, (a) commissions
to unrelated third parties, (b) trade, cash, and quantity discounts, (c) payment terms, credits and allowances (including those granted on account of price adjustments) given or made in the ordinary course of business, (d) allowances
for damaged Products, rejections and returns, (e) chargeback payments and rebates (or the equivalent thereof) granted to group purchasing organizations, managed health care organizations or to federal, state/provincial, local or other
governments, including their agencies, or to wholesalers or distributors, (f) Product specific marketing fees granted to group purchasing organizations or wholesalers, managed health care organizations, wholesalers or distributors pursuant to
agreements negotiated by SAGENT with such entities, (g) administration fees payable to buying groups such as group purchasing organizations, wholesalers or distributors, (h) freight and chargebacks, (i) Medicaid and Medicare rebates,
(j) cash discounts, (k) [***], and (l) sales, value-added (to the extent not refundable in accordance with applicable law) and other taxes paid on or in relation to sales of the Product all as calculated in accordance with U.S.
generally accepted accounting principles. 
 1.27 “Product” shall have the meaning set forth in the Recitals.

 1.28 “Quality Agreement” means that certain Quality Assurance Agreement entered into by the Parties as of
the Effective Date which sets forth (a) the roles and responsibilities of DOBFAR and/or its affiliates and SAGENT with respect to the quality assurance for the Product, and (b) how the Parties’ quality operations shall interact with
each other in connection with same. 
 1.29 “Registration” shall mean approval of a Registration Application
for the Product filed by DOBFAR relating to the manufacturing, use, marketing and sale, and/or pricing and reimbursement when applicable, of the Product. 
 1.30 “Registration Application” shall mean any filing(s) made by DOBFAR under this Agreement with a Governmental Authority in the Territory for regulatory approval of the manufacture,
use, marketing and/or sale, and/or pricing and reimbursement when applicable, of the Product including, without limitation, any amendments or supplements thereto. 

  
 3 

 CONFIDENTIAL TREATMENT 
 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. This text has been separately filed with the Securities and Exchange Commission 

 
 1.31 “Receiving Party” shall have the
meaning set forth in Section 12.1. 
 1.32 “Renewal Term” shall have the meaning set forth in
Section 2.1. 
 1.33 “Sales and Distribution Expenses” shall mean [***] as determined on a quarterly basis
by SAGENT and in accordance with industry standard. 
 1.34 “Specifications” shall mean the approved
specifications for the manufacture, storage, handling, labeling and packaging of the Product as the same may be amended from time to time. 
 1.35 “Territory” shall the fifty states of the United States of America, the District of Columbia, the Commonwealth of Puerto Rico, all territories and possessions of the United States of
America, United States military bases, and any other location over which the FDA has jurisdiction to regulate medicinal products intended for human use. 
 1.36 “Third Party” shall mean any person or entity who or which is neither a Party nor an Affiliate of a Party. 
 1.37 “Trademark” means any trademark, trade name, trade dress, slogan, logo, copyright or similar item selected by SAGENT for use in connection with the Product. 

ARTICLE 2 

TERM 
 2.1
This Agreement shall become effective on the date hereof and, unless earlier terminated as provided in Article 13, shall terminate five (5) years (the “Initial Term”) after the Commercial Launch Date, provided, however, that
SAGENT shall have the option, which option it may exercise in its sole discretion by giving written notice to DOBFAR, to renew the Agreement for successive additional one (1) year terms (each a “Renewal Term”) unless DOBFAR has
given written notice to SAGENT at least one (1) year prior to the expiration of the Initial Term, or at least six (6) months prior to the expiration of a Renewal Term. The “Term” of this Agreement shall be deemed to refer
to the Initial Term and any Renewal Terms. 
 ARTICLE 3 

DEVELOPMENT OF THE PRODUCT 
 DOBFAR shall solely own all Registrations and Registration Applications in the Territory relating to the Product. If requested by DOBFAR, SAGENT will give reasonably necessary support for the
administrative activities related to the filing of the ANDA. 
 ARTICLE 4 

COMMERCIALIZATION OF THE PRODUCT 
 4.1 On the Approval Date and throughout the Term of this Agreement, DOBFAR hereby represents, covenants and agrees that it shall certify to SAGENT the following: 

4.1.1 DOBFAR is, and will remain, the sponsor and sole owner of the ANDA, that such ANDA has been duly approved by the FDA, that to date
DOBFAR has diligently maintained each such ANDA in full force and effect, and that DOBFAR will maintain such ANDA in full force and effect; 

  
 4 

 4.1.2 DOBFAR has obtained, and will maintain, full approval from the FDA and any other
applicable Governmental Authorities permitting the manufacture of the Product and the use, marketing and sale of the Product in the Territory; 
 4.1.3 The Product and all intermediaries used in the manufacture thereof have been developed in accordance with their respective Specifications, in a good scientific manner, and in compliance in all
material respects with all requirements of applicable laws, rules and regulations, and all other requirements of any applicable cGMP, good laboratory practice and current good clinical practice; 

4.1.4 The Product has been developed in such a manner such that its manufacture and supply does not infringe, or will not infringe, the
intellectual property rights of any Third Party; 
 4.1.5 The Product has not been recalled, suspended or discontinued as a
result of any action by the FDA or any other similar foreign governmental entity, regardless of whether made or sold by DOBFAR or any licensee, distributor or marketer in the Territory or outside of the Territory; 

4.1.6 DOBFAR has not received any written notice that the FDA or any other Governmental Authority has commenced, or threatened to
initiate, any action to withdraw approval, place marketing or sale restrictions, or request the recall of the Product, or commenced, or threatened to initiate, any action to enjoin or place restrictions on the production, sale, marketing or
reimbursement of the Product; 
 4.1.7 DOBFAR has not used, and will not use at any time during the term of this Agreement, in
any capacity, the services of any person debarred under the U.S. Generic Drug Enforcement Act, 21 USC §335a(k)(1) and further has not used, and will not use at any time during the term of this Agreement, any person who has been convicted of a
crime as defined under the U. S. Generic Drug Enforcement Act in connection with any of the services provided under this Agreement or the Supply Agreement; and 
 4.1.8 Performance of any of the terms and conditions of this Agreement by DOBFAR will not constitute any breach or violation of any agreement or understanding, written or oral, government or court decree
or order to which it is a party or by which it is bound. 
 4.2 SAGENT shall have the right to engage in the distribution,
marketing and sales of the Product in the Territory (the “Marketing Activities”), which shall include, but not be limited to: 
 4.2.1 carrying out the distribution, marketing, advertising, promotional and sales of each Product as it deems necessary or useful in its sole discretion; and 

4.2.2 keeping DOBFAR informed through written reports which are to be made by SAGENT when and if material developments in the market for
the Product arises, which reports shall be summaries of such material developments. 
 4.3 On the Approval Date and throughout
the Term of this Agreement, WORLDGEN hereby represents, covenants and agrees that it shall certify to SAGENT that WORLDGEN has not used, and will not use at any time during the term of this Agreement, in any capacity, the services of any person
debarred under the U.S. Generic Drug Enforcement Act, 21 USC §335a(k)(1) and further has not used, and will not use at any time during the term of this Agreement, any person who has been convicted of a crime as defined under the U. S. Generic
Drug Enforcement Act in connection with any of the services provided under this Agreement or the Supply Agreement. 

  
 5 

 ARTICLE 5 
 RESPONSIBILITY FOR COSTS AND EXPENSES 
 5.1 DOBFAR shall itself bear, and
SAGENT shall have no liability with respect to, any and all costs and expenses incurred by DOBFAR in providing the Services in accordance with this Agreement. 
 5.2 In full consideration of DOBFAR providing the Services with respect to the Product and appointing SAGENT as a distributor of the Product in the Territory, SAGENT shall pay to WORLDGEN the payments in
accordance with the requirements of Exhibit B (the “Milestone Payment”). 
 5.3 All payments required
under this Agreement shall be made in United States Dollars ($USD), via wire transfer of immediately available funds as directed by the other Party from time to time. 
 ARTICLE 6 
 SUPPLY 

6.1 During the term of this Agreement, DOBFAR shall manufacture, label and package, ship and deliver the Product for SAGENT on the terms
and conditions specified in this Agreement and in compliance with all requirements of applicable laws, rules and regulations, and all other requirements of any applicable cGMP and Specifications. The Product shall be manufactured by DOBFAR at the
applicable Manufacturing Facility in accordance with the terms of this Agreement and the Quality Agreement. Except as set forth in Section 7.1, SAGENT shall not be required to order any fixed minimum quantity of Product or any quantity of
Product for which it does not actually have a need, notwithstanding any forecast or prior course of dealing. 
 6.2 During the
term of this Agreement, DOBFAR shall be solely responsible for arranging for an FDA-approved third party to manufacture and supply the API necessary to manufacture the Product in accordance with all requirements of applicable laws, rules and
regulations, and all other requirements of any applicable cGMP and Specifications and in sufficient quantities to meet SAGENT’s forecasted needs for the Product; provided that DOBFAR shall give written notice to SAGENT in advance of retaining
any such third party API supplier. With respect to any third party API supplier that DOBFAR desires to use, DOBFAR shall ensure that such third party API supplier makes its facilities and records relating to the manufacture of the API available for
inspection by SAGENT as SAGENT requests from time to time. In the event that during any such inspection, SAGENT identifies any instances of noncompliance with the requirements of applicable laws, rules and regulations, applicable cGMP or the
Specifications, then DOBFAR shall promptly provide a written plan for correcting such deficiencies (including a proposed timetable for implementing such corrections) and shall ensure that such deficiencies are corrected, at DOBFAR’s or such
third party API supplier’s sole expense, as soon as reasonably practicable. If not corrected to SAGENT’s satisfaction (or if the third party API supplier does not make its facility and records available for inspection by SAGENT), then
DOBFAR shall be required to secure a different third party API supplier, and to immediately cease using the noncompliant supplier. Subject to Section 6.3, DOBFAR shall be solely responsible for ensuring that the API so supplied to it is of
sufficient quality and meets other relevant standards in order for it to be utilized by DOBFAR in the manufacture of the Product in accordance with Section 6.1. 

  
 6 

 CONFIDENTIAL TREATMENT 
 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. This text has been separately filed with the Securities and Exchange Commission 

 
 6.3 All Product manufactured, shipped and delivered by DOBFAR
to SAGENT or SAGENT’s designees under this Agreement shall be packaged and labeled in accordance with this Agreement and the then-current packaging and labeling guidelines provided by SAGENT and in compliance with all requirements of applicable
laws, rules and regulations, all other requirements of any applicable cGMP as well as the applicable Specifications and the Registration. SAGENT shall supply DOBFAR with SAGENT’s NDC number(s) for the Product and any trade dress that SAGENT
wishes to have included in the labeling for the Product. DOBFAR shall print, either directly or through a third party, labels and other printed material to be included as part of the Product, and the cost of doing so shall be reflected in the price
charged by DOBFAR for the Product pursuant to Article 9. From time to time, SAGENT may provide DOBFAR with modified trade dress or logos and upon receipt thereof, DOBFAR shall use its commercially reasonable efforts to incorporate such changes on
the Products in accordance with SAGENT’s request. DOBFAR shall provide SAGENT with any modifications to the labeling for the Products as promptly as possible in order to ensure compliance with any and all applicable regulations. SAGENT shall
reimburse DOBFAR for all reasonable costs incurred by DOBFAR in making modifications to labeling, branding, or imprinting packaging and/or manufacturing processes to accommodate SAGENT’s new labeling or to accommodate any other changes
requested by SAGENT. Such reimbursement shall be made pursuant to invoices submitted by DOBFAR to SAGENT, undisputed amounts on such invoices shall be payable within thirty (30) days after SAGENT’s receipt thereof. SAGENT shall cooperate
with DOBFAR to ensure that the labeling of the Product complies with the Registration for the Product. 
 6.4 DOBFAR shall
schedule its manufacturing operations so that all Products delivered have the maximum shelf life possible and in any event no Product delivered hereunder shall have less than [***] of shelf life, based on the dating included on such Product’s
packaging, remaining at the time of delivery; provided, however, that if SAGENT accepts delivery of Product prior to the Launch Date and such Product has less than [***] of shelf life, based on the dating included on such Product’s packaging,
as of the Launch Date, then DOBFAR will, at no expense to SAGENT, replace such Product as soon as practicable with Product that has at least 75% of shelf life, based on the dating included on such Product’s packaging, as of the later of
(i) the Launch Date or (ii) the date such replacement Product is actually delivered to SAGENT. 
 ARTICLE 7

 FORECASTS AND PURCHASE ORDERS 
 7.1 SAGENT has supplied WORLDGEN with an initial non-binding forecast showing SAGENT’s estimated monthly requirements for Product for the twelve-month (12-months) period commencing on the anticipated
Commercial Launch Date. Promptly following the Commercial Launch Date and thereafter on the first day of the first month during each calendar quarter during the term hereof, SAGENT shall deliver to WORLDGEN an updated forecast for the twelve-month
(12-month) period commencing on the first day of the immediately following calendar quarter for Product. It is understood that SAGENT before signing a supply agreement with a group purchasing organization will check with WORLDGEN as to the capacity
of DOBFAR to produce such quantities in the time frame required. In addition, SAGENT shall notify WORLDGEN in writing as soon as practicable after it enters into any written agreement with a group purchasing organization with respect to the sale of
the Product in the Territory. SAGENT shall place purchase orders for at least the quantity of such Product specified in the first three (3) months of each forecast and the remaining nine (9) months shall be a good faith estimate; provided,
however, that with respect to forecasts given by SAGENT to WORLDGEN prior to the Approval Date SAGENT will have no firm obligation to purchase Product prior to the Launch Date. Notwithstanding anything in this Agreement to the contrary, DOBFAR shall
guarantee manufacturing capacity and the ability to supply SAGENT 

  
 7 

 CONFIDENTIAL TREATMENT 
 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. This text has been separately filed with the Securities and Exchange Commission 

 
 
[***] of SAGENT’s annual forecasted quantity, and provided that SAGENT has complied with all provisions of this Section 7.1, in the event DOBFAR fails to supply such quantities, and
SAGENT is required to pay inability payments to any customer of SAGENT’s, then DOBFAR shall reimburse SAGENT for all such inability payments. In the event that SAGENT’s requests for quantities of Product exceed the quantities provided for
in the forecasts that have been submitted, DOBFAR shall use reasonable commercial efforts to supply such an increase in quantity. 
 7.2 SAGENT shall place firm purchase orders with WORLDGEN for its requirements of Product in full Batch quantities at least [***] prior to the requested date of delivery; provided that, if requested by
SAGENT, DOBFAR shall use commercially reasonable efforts to deliver Product at such earlier time as SAGENT reasonably requests. Each firm written purchase order, signed by SAGENT’s duly authorized representative, shall authorize DOBFAR to
manufacture such quantities of the Product as are set forth therein. Each purchase order shall be deemed accepted upon receipt, and DOBFAR shall deliver Product in accordance with such purchase order; provided, however, that if the quantity of
Product set forth in a purchase order exceeds the most recent firm forecast for Product for the month to which such purchase order relates, then DOBFAR shall use its commercially reasonable best efforts to supply the quantity of Product in excess of
the firm forecasted amount in accordance with such purchase order, but shall not be deemed to have breached this Agreement if it cannot supply such excess Product. 
 ARTICLE 8 
 SHIPPING AND DELIVERY 

8.1 Unless otherwise agreed upon in writing and subject to Article 7 above, shipping and delivery dates will be provided by SAGENT at the
time firm purchase orders are placed. The parties hereby acknowledge that DOBFAR intends to ship Product by sea or air, as required by SAGENT. 
 8.2 A bill of lading will be furnished to SAGENT with respect to each shipment. At delivery, Product will be free and clear of any liens or encumbrances placed thereon by DOBFAR. 

8.3 Each shipment of Product hereunder will be delivered EX WORKS [***]. DOBFAR shall procure an approved shipping vendor authorized to
ship pharmaceutical products upon reasonable notice to SAGENT. DOBFAR shall include with each shipment of Product a Certificate of Analysis and all technical documentation as specified in the Quality Agreement. 

8.3.1 Notification by SAGENT to DOBFAR of partial loss, damage, or non-delivery of any separate part of a shipment shall be made promptly
by SAGENT after delivery to SAGENT, and if loss, damage, or partial non-delivery are not evident to SAGENT at the time of delivery, such notification by SAGENT to DOBFAR shall be made no later than thirty (30) days after delivery to SAGENT (the
“Discovery Date”). Notwithstanding the foregoing, in the event SAGENT discovers that a shipment of Product contains latent defects after the Discovery Date, each of SAGENT and DOBFAR shall use commercially reasonable efforts to
mutually agree on an appropriate remedy reasonably acceptable to the Parties. 
 8.4 In the event of partial or full loss or
non-delivery of a shipment, the Parties will cooperate to insure that notification and follow-up with the involved ground and air carriers and customs or other warehouses is made in order to determine if such missing delivery can be located. For any
shipment which is not recovered or which is damaged or defective, the Parties shall agree to a schedule for the manufacture of additional Product by DOBFAR. 

  
 8 

 CONFIDENTIAL TREATMENT 
 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. This text has been separately filed with the Securities and Exchange Commission 

 

 ARTICLE 9 
 COMPENSATION 
 9.1 In consideration of the Product manufactured and
supplied by DOBFAR to SAGENT hereunder, SAGENT shall pay to WORLDGEN as follows: 
 9.1.1 With respect to each unit of Product
supplied to SAGENT hereunder, SAGENT shall pay the Transfer Price to WORLDGEN net [***] days from the invoice date which shall be no earlier than the date of actual shipment; and 

9.1.2 SAGENT shall pay to WORLDGEN, for the account of DOBFAR within [***] days of the end of each calendar quarter during
the Term, [***] of the NET MARGIN for such calendar quarter. 
 ARTICLE 10 

RECALLS, PRODUCT COMPLAINTS AND OTHER REGULATORY MATTERS 
 10.1 Each Party shall, within 24 hours, notify the other Party of any notification or other information whether received directly or indirectly, which might affect the marketability, quality, safety, or
effectiveness of the Product and/or which might result in the recall of the Product. 
 10.2 Within twenty-four (24) hours
of a determination that a withdrawal or a recall of a Product may be necessary and prior to notifying the FDA, DOBFAR shall notify SAGENT so that SAGENT may participate in a decision whether the Product shall be withdrawn or recalled, but DOBFAR
shall make the final decision whether the Product is withdrawn or recalled based on compliance with DOBFAR’s quality systems and procedures. Notwithstanding the foregoing, SAGENT shall have the right to withdraw or recall the Product in its
sole discretion if it believes that such a withdrawal or recall is necessary or appropriate. SAGENT shall reasonably assist DOBFAR in DOBFAR’s investigation to determine the cause and extent of the problem. 

10.3 DOBFAR shall perform the withdrawal or recall of the Products supplied to SAGENT under this Agreement, subject the remainder of this
Article 10. 
 10.4 In the event of any recall arising out of or resulting from DOBFAR’s failure to manufacture Product in
compliance with cGMP and/or the Specifications, in addition to any other rights and remedies of SAGENT, DOBFAR shall, at the election of SAGENT, either: 
 10.4.1 supply Product, without charge to SAGENT, in an amount sufficient to replace the amount of Product recalled; or 
 10.4.2 give a credit to SAGENT against outstanding Net Margin Share due from SAGENT in amounts equal to the price paid to DOBFAR by SAGENT for the Product so recalled. 

10.5 In the event of any such recall as contemplated in Article 10.4 arises out of or results primarily and directly from DOBFAR’s
failure to manufacture Product in compliance with cGMP and/or the Specifications, DOBFAR shall pay to SAGENT, in addition to the amounts set out in Section 10.4, (i) SAGENT’s out-of pocket expenses (including, without limitation,
attorneys fees) incurred in connection with such recall or addressing such failure by DOBFAR, and (ii) any and all third party liability resulting in connection with any of the foregoing. 

  
 9 

 10.6 With respect to recalls not covered by Section 10.4, in the event any such recall
arises out of or results from primarily and directly from SAGENT’s negligence in its distribution of Product not in compliance with FDA’s regulations, SAGENT shall pay to DOBFAR or WORLDGEN, as applicable (i) DOBFAR or WORLDGEN’s
out-of pocket expenses (including, without limitation, attorneys fees) incurred in connection with such recall or addressing such failure by SAGENT, and (ii) any and all third party liability resulting in connection with any of the foregoing.

 10.7 The Parties shall be responsible for the handling of all Product complaints, including those associated with
manufacturing and packaging, in accordance with the allocation of responsibilities set forth in the Quality Agreement. Each Party shall fully cooperate with the other Party in connection with the handling of all Product complaints. 

10.8 DOBFAR shall be responsible for the reporting of all adverse drug experiences of the Products as required by the FDA and other
regulatory bodies and Applicable Law. 
 ARTICLE 11 

INDEMNIFICATION 
 11.1 SAGENT shall indemnify, defend and hold DOBFAR, its Affiliates, officers, directors, agents, servants and employees harmless against all claims, losses, actions, damages (including injuries to, or
death of any person, or injury to, or destruction of, property), liabilities and expenses (including reasonable attorneys fees) and costs of investigating and defending against lawsuits, complaints, actions or other pending or threatened litigation
(“Costs”) arising out of or attributable to (i) SAGENT’s breach of or any inaccuracy in any of its representations, warranties, covenants or agreements made under this Agreement or in any certificate, instrument or other
document delivered by SAGENT to DOBFAR pursuant to this Agreement; (ii) the gross negligence or willful misconduct of SAGENT, its officers, directors, agents, servants and employees relating to this Agreement; or (iii) any recall
attributable to SAGENT’s performance hereunder; or (iv) any claims or demands relating to a Product that are commenced by Bristol-Myers Squibb Company between the Effective Date and the patent expiry date against DOBFAR based on the
activities of SAGENT pursuant to this Agreement. 
 11.2 DOBFAR shall indemnify, defend and hold SAGENT, its Affiliates
officers, directors, agents, servants and employees harmless against Costs relating to: (i) any injury claim or damage resulting from or caused by the manufacture of any of the Products, operation of any Manufacturing Facility or any product
defects with respect to any of the Products, including injuries to persons and property arising from such product defects; (ii) the failure of DOBFAR, its officers, directors, agents, servants and employees to comply with Applicable Laws;
(iii) any inaccuracy in or breach of any of DOBFAR’s and/or WORLDGEN’s representations, warranties, covenants or agreements made under this Agreement or in any certificate, instrument or other document delivered by DOBFAR (or
WORLDGEN, as applicable) to SAGENT pursuant to this Agreement; (iv) the negligence of DOBFAR, its officers, directors, agents, servants and employees relating to this Agreement; (v) any recall attributable to DOBFAR’s and/or
WORLDGEN’s performance hereunder (including without limitation amounts SAGENT may pay or credit to its customers for Product so recalled); (vi) any claims made by Third Parties relating to any supplier of API pursuant to this Agreement;
(vii) Section 7.3 hereto, (viii) any intellectual property litigation with respect to a Product (except for section 11.1(iii)), or (ix) the negligence of WORLDGEN, its officers, directors, agents, servants and employees relating
to this Agreement. 
 11.3 Promptly after the receipt by either DOBFAR or SAGENT of notice or otherwise becoming aware of
(a) any claim or (b) the commencement of any action or proceeding which may give rise to a claim for indemnification hereunder, such Party (the “Indemnitee”) will, if a

  
 10 

 
claim with respect thereto is to be made against the Party or Parties obligated to provide indemnification pursuant to this Article 12 (the “Indemnitor”), give such Indemnitor
written notice of such claim or the commencement of such action or proceeding and, shall permit the Indemnitor to assume, at its own expense, the defense of any such claim, action or proceeding, or any litigation resulting from such claim, and, upon
such assumption, shall cooperate fully with the Indemnitor in the conduct of such defense. The Indemnitee shall permit the Indemnitor, at its discretion, to settle any such claim, action or proceeding, provided, however, that such
settlement does not adversely affect the Indemnitee’s rights hereunder or impose any obligations on the Indemnitee, in addition to those set forth herein, in order for it to exercise such rights. No such claim, action or proceeding shall be
settled without the prior written consent of the Indemnitor and the Indemnitor shall not be responsible for any Costs incurred other than as provided herein. The Indemnitee, its Affiliates and their respective directors, officers, employees and
agents shall cooperate fully with the Indemnitor and its legal representatives in the investigation and defense of any claim, action or proceeding covered by this indemnification. The Indemnitee shall have the right, but not the obligation, to be
represented by counsel of its own selection and expense. 
 11.4 If the Indemnitor shall not assume the defense of any such
claim or litigation resulting therefrom, the Indemnitee may defend against such claim or litigation in such manner as it may deem appropriate and the Indemnitee may settle such claim or litigation on such terms as it may deem appropriate, and the
Indemnitor shall promptly reimburse the Indemnitee for the amount of all Costs incurred by the Indemnitee in connection with the defense against or settlement of such claim or litigation. If no settlement of such claim or litigation is made, the
Indemnitor shall promptly reimburse the Indemnitee for the amount of any Costs incurred by the Indemnitee in the defense against such claim or litigation. 
 ARTICLE 12 
 CONFIDENTIALITY AND NON-USE 

12.1 During the term of this Agreement, a Party (the “Disclosing Party”) may disclose to any other Party, its
affiliates, directors, officers, employees and agents (the “Receiving Party”) certain confidential information that the Disclosing Party considers confidential and proprietary (the “Confidential Information”). The
Receiving Party shall keep Confidential Information confidential and such Confidential Information shall not, without the Disclosing Party’s prior written consent, be disclosed by the Receiving Party to any person or entity not a party to this
Agreement in any manner whatsoever in whole or in part, and shall not be used by a Receiving Party other than in connection with the purposes contemplated by this Agreement. Confidential Information shall be disclosed only to the officers and
employees of the Receiving Party who need to know such Confidential Information for the purposes of this Agreement. The Receiving Party hereto agrees that, unless required by applicable law or legal process, it will not disclose to any third party
Confidential Information, nor use such Confidential Information it receives from the Disclosing Party, for any purpose other than that contemplated under this Agreement. 
 12.2 Such Confidential Information shall not be considered confidential, nor subject of this Agreement if it: 
 12.2.1 Was rightfully in the possession of the Receiving Party, without obligation of secrecy, prior to the date of disclosure of such Confidential Information by the Disclosing Party to the Receiving
Party; or 
 12.2.2 Was publicly known on or prior to the date of disclosure to the Receiving Party; or 

  
 11 

 12.2.3 Becomes publicly known, except by a breach of this Agreement by the Receiving Party;
or 
 12.2.4 Is subsequently disclosed to the Receiving Party by a third party who, to the knowledge of the Receiving Party
after reasonable inquiry, did not receive it under any obligation of confidentiality to the Disclosing Party; or 
 12.2.5 Is
developed by or for the Receiving Party independent of the disclosures made under this Agreement; or 
 12.2.6 Is required to be
disclosed by applicable law, governmental regulation or legal process, provided that the Receiving Party promptly notifies the Disclosing Party of the requirement of such disclosure. 

12.3 The Disclosing Party shall not be required to disclose any information to the other which the Disclosing Party may be legally
restricted from so disclosing under the terms of any agreement between the Disclosing Party and third parties. 
 12.4 Upon the
Disclosing Party’s written request, the Receiving Party shall promptly return all Confidential Information and shall destroy any other material prepared (or portion thereof) which contain Confidential Information. Promptly thereafter, the
Receiving Party shall notify the Disclosing Party in writing that all Confidential Information has been returned or destroyed in accordance with the foregoing, except that the Receiving Party may keep one copy of Confidential Information to be used
only to prove compliance with the terms of this Agreement. 
 12.5 The obligations set forth in this Article shall survive
expiration or termination of this Agreement for a period of five (5) years. 
 12.6 Neither DOBFAR nor SAGENT shall release
to any third party or publish in any way any non-public information with respect to the terms of this Agreement without the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed; provided,
that SAGENT may disclose the terms of this Agreement as reasonably necessary or useful in connection with the development, commercialization and/or divestiture or other disposition of the Product and either Party may disclose the terms
of this Agreement: 
 12.6.1 to the extent required to comply with applicable laws, including, without limitation the rules and
regulations promulgated by the United States Securities and Exchange Commission; provided, further, that prior to making any such disclosure, the Party intending to so disclose the terms of this Agreement shall provide the
non-disclosing Party with written notice of the proposed disclosure and an opportunity to review and comment on the intended disclosure which is reasonable under the circumstances; or 

12.6.2 to one or more third parties and/or their advisors in connection with a proposed spin-off, joint venture, divestiture, merger or
other similar transaction involving all, or substantially all, of the assets or business of the disclosing Party to which this Agreement relates or to lenders, investment bankers and other financial institutions of its choice solely for purposes of
financing the business operations of such Party; provided, further, that either (i) upon the written consent of the other Party or (ii) if the disclosing Party uses reasonable efforts to obtain a signed confidentiality
agreement with such third parties with respect to such information on terms no less restrictive than those contained in this Article 13. 

  
 12 

 ARTICLE 13 
 TERMINATION 
 13.1 This Agreement may be terminated at any time by a Party
upon the breach of any material provision of this Agreement by the other Party if the breach is not cured within sixty (60) days after written notice thereof to the Party in default specifying in reasonable detail the nature of such breach.

 13.2 SAGENT may terminate this Agreement at any time by giving sixty (60) days written notice to DOBFAR if:
(i) SAGENT, in its sole discretion, determines that it will no longer market the Product; or (ii) any Governmental Authority (a) withdraws approval of the manufacture or marketing of the Product, (b) takes any action the result
of which is to prohibit the manufacture, packaging, labeling, storage, importation, sale or use or any similar action of the Product, the API or any raw material contained therein or to impose a significant restriction on the manufacture, packaging,
labeling, storage, importation, sale, use or similar action, or (c) makes a final decision preventing the use of the Product in humans. 
 13.3 In the event that a Party shall have become insolvent or bankrupt, or shall have made an assignment for the benefit of its creditors, or there shall have been appointed a trustee or receiver of such
Party for all or a substantial part of its property, or any case or proceeding shall have been commenced or other action taken by or against such Party (as to which, if involuntarily commenced against such Party, such Party is not able to obtain
dismissal within sixty (60) days after commencement thereof) in bankruptcy or seeking reorganization, liquidation, dissolution, winding-up, arrangement, composition or readjustment of its debts or any other relief under any bankruptcy,
insolvency, reorganization or other similar act or law of any jurisdiction now, or hereafter, in effect, then such Party shall not be relieved in any respect of its obligations hereunder, and, in addition to any other remedies available to it at law
or in equity, the other Party may terminate this Agreement, by giving written notice, which shall be effective immediately upon delivery of such notice or at such later date specified therein. 

13.4 Upon expiration or termination of this Agreement, whichever is sooner, DOBFAR shall manufacture and ship to SAGENT, and SAGENT shall
purchase in accordance with the provisions hereof all amounts of the Product ordered pursuant to purchase orders issued hereunder prior to the date on which notice of such termination is given, or prior to the expiration date, as applicable.

 13.5 Termination, relinquishment or expiration of this Agreement in its entirety or with respect to any Product for any
reason shall be without prejudice to any rights that shall have accrued to the benefit of either Party prior to such termination, relinquishment or expiration. Such termination, relinquishment or expiration shall not relieve either Party from
obligations that are expressly indicated to survive termination or expiration of this Agreement. 
 ARTICLE 14 

FORCE MAJEURE 
 14.1 Any delay in the performance of any of the duties or obligations of either Party (except the payment of money due hereunder) shall not be considered a breach of this Agreement and the time required
for performance shall be extended for a period equal to the period of such delay only if such delay has been caused by or is the result of any acts of God; acts of a public enemy; insurrections; riots; embargoes; labor disputes (including strikes,
lockouts, job actions, or boycotts); fires; explosions; floods; shortages of material or energy or other unforeseeable causes; in each case, which are beyond the reasonable control and without the fault or negligence of the Party so affected.
Notwithstanding anything to the contrary, in no event shall the failure of a third party supplier to supply the necessary quantities of API be deemed a force majeure event. The Party so affected shall give prompt notice to the other Party of such
cause, and shall take whatever reasonable steps are necessary to relieve the effect of such cause as rapidly as reasonably possible. Notwithstanding the forgoing, if DOBFAR is 

  
 13 

 CONFIDENTIAL TREATMENT 
 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. This text has been separately filed with the Securities and Exchange Commission 

 

 
unable to perform its obligations hereunder as a result of one or more such force majeure events for a period longer than three (3) months, SAGENT shall have a right to terminate this
Agreement with such failure being deemed an uncured breach of this Agreement with respect to which no additional cure period is required to be given. 
 14.2 Notwithstanding Section 16.1 or anything else in this Agreement, in the event that DOBFAR gives SAGENT notice that it will not be able to deliver the forecasted amounts of the Products pursuant
to Article 7 or in fact DOBFAR does not deliver such forecasted amounts, in addition to any other rights and remedies SAGENT may have, DOBFAR shall use its best efforts to qualify one or more alternative suppliers of such Products. Such cooperation
shall include, but not be limited to, technical transfer of the manufacturing process to such third party suppliers as well as necessary and useful transfer of know-how relating to same. 

ARTICLE 15 

INSURANCE 

15.1 Each Party shall maintain during the Initial Term and any Renewal Terms insurance in such amounts and against such risks as is
customary by companies engaged in the same or similar business and similarly located, and shall, upon request, furnish evidence of such insurance. 
 15.2 Without prejudice to any rights or remedies SAGENT may have under this Agreement or otherwise at law generally, SUPPLIER shall (at SUPPLIER’s sole cost and expense) maintain in full force and
effect adequate product liability insurance (including for these purposes insurance covering the risks and liabilities arising out of SUPPLIER’s breach of this Agreement) with annual coverage of at least [***] occurrence and [***] in the
aggregate, during the Term. SUPPLIER will provide SAGENT with evidence of such insurance of upon request and such insurance shall name SAGENT as an additional insured. 
 15.3 Without prejudice to any rights or remedies SUPPLIER may have under this Agreement or otherwise at law generally, SAGENT shall (at its sole cost and expense) maintain self insurance. 

15.4 SUPPLIER represents, warrants and covenants that nothing has or will be done or be omitted to be done that may result in any of the
said insurance policies being or becoming void, voidable or unenforceable during the Initial Term or any Renewal Terms of this Agreement. 
 15.5 With respect to any Third Party insurance coverage required hereunder, if requested, each Party will provide the other with documentation evidencing the above and showing the name of the issuing
company, the policy number, the effective date, the expiration date and the limits of liability. Any insurance required herein shall provide for a minimum of thirty (30) days’ written notice to the insured of a cancellation of, or material
change in, the insurance. 
 ARTICLE 16 
 MISCELLANEOUS 
 16.1 Interpretation. DOBFAR and SAGENT hereby
acknowledge and agree that the Quality Agreement is intended as a supplement to, not a replacement for, this Agreement. Accordingly, the parties intend that the minimum requirements relating to the manufacture and supply of Product are set forth in
this Agreement and that specific additional requirements relating to the same are set forth in the Quality Agreement. In the event of a perceived conflict 

  
 14 

 
between the terms and conditions of this Agreement and the Quality Agreement, SAGENT and DOBFAR shall promptly convene to discuss in good faith and attempt to promptly resolve such perceived or
actual conflict. Notwithstanding anything to contrary, however, in no event shall DOBFAR’s obligations under this Agreement be deemed to be reduced by any provision of the Quality Agreement. 

16.2 Assignment. This Agreement shall be binding upon the successors and assigns of the Parties. DOBFAR and/or WORLDGEN may not
assign any interest under this Agreement without the prior written consent of SAGENT. SAGENT may not assign any interest under this Agreement without the prior written consent of DOBFAR, which shall not be unreasonably withheld, except that no such
consent shall be required to assign this Agreement to (i) an Affiliate of SAGENT; or (ii) a third party in connection with the sale or transfer to such third party of all or substantially all of the business or assets to which this
Agreement relates. Any purported assignment without a required consent shall be void. No assignment shall relieve any Party of responsibility for the performance of any obligation, which accrued prior to the effective date of such assignment.

 16.3 Governing Law; Language; Submission to Jurisdiction. This Agreement shall be governed by the laws of the State of
New Jersey without regard to any conflicts of laws or principles. The Parties consent to the exclusive jurisdiction of the state and federal courts located within the State of New Jersey. 

16.4 Severability. If any of the provisions of this Agreement are held invalid or unenforceable, unless the invalidity or
unenforceability substantially frustrates the underlying intent and sense of the remainder of the Agreement, such invalidity or unenforceability shall not affect the validity or enforceability of any other provision of this Agreement, except those
where the invalidated or unenforceable provision comprises an integral part of, or are otherwise clearly inseparable from, the intent and sense of the Agreement. In the event any provision is held invalid or unenforceable, the Parties will attempt
to agree upon a valid and enforceable provision which shall be a reasonable substitute for such invalid or unenforceable provision in light of the intent and sense of this Agreement and, upon so agreeing, shall incorporate such substitute provision
in this Agreement. 
 16.5 Publicity. No press release, publicity or other form of public written disclosure related to
this Agreement shall be permitted by either Party to be published or otherwise disclosed unless the other Party has indicated its consent to the form of the release in writing, except for any disclosure as is deemed necessary, in the reasonable
judgment of the responsible Party, to comply with Applicable Laws with respect to regulatory reporting or disclosure obligations. 
 16.6 Independent Contractor. Each Party is acting under this Agreement as an independent contractor and not as the agent or employee of the other. Each Party understands and agrees that it has no
authority to assume any obligation on behalf of the other Party and that it shall not hold out to third parties that it has any authority to act on the other Party’s behalf except as expressly permitted herein. Unless otherwise expressly stated
herein, each Party shall be responsible for its own expenses relating to its performance under this Agreement and shall not incur expenses for the other Party’s account unless expressly authorized herein or by subsequent written agreements.

 16.7 Waiver. No waiver or modification of any of the terms of this Agreement shall be valid unless in writing and
signed by an authorized representative of both Parties hereto. Failure by either Party to enforce any rights under this Agreement shall not be construed as a waiver of such rights nor shall a waiver by either Party in one or more instances be
construed as constituting a continuing waiver or as a waiver in other instances. 

  
 15 

 CONFIDENTIAL TREATMENT 
 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. This text has been separately filed with the Securities and Exchange Commission 

 

 16.8 Relationship between the Parties. Each Party is acting under this Agreement
as an independent contractor and not as the agent or employee of the other. Each Party understands and agrees that it has no authority to assume any obligation on behalf of the other Party and that it shall not hold out to third parties that it has
any authority to act on the other Party’s behalf except as expressly permitted herein. Unless otherwise expressly stated herein, each Party shall be responsible for its own expenses relating to its performance under this Agreement and shall not
incur expenses for the other Party’s account unless expressly authorized herein or by subsequent written agreements. 

16.9 Notices. Unless otherwise specified herein, all notices required or permitted to be given under this Agreement shall be in
writing and shall be (a) delivered personally, (b) sent by registered mail, return receipt requested, postage prepaid, (c) sent by a nationally-recognized courier service guaranteeing next-day or second day delivery, charges prepaid,
or (d) delivered by facsimile (with the original promptly sent by any of the foregoing manners), to the addresses or facsimile numbers of the other Party set forth below, or at such other addresses as may from time to time be furnished by
similar notice to any Party. The effective date of any notice hereunder shall be the date of receipt by the receiving Party. 

If to DOBFAR: 

A.C.S. DOBFAR 

Viale Addetta, 4/12 
 20067 Tribiano (MI) 
 Italy 

Attention: [***] 

Facsimile No. [***] 
 If to SAGENT: 
 Sagent Pharmaceuticals, Inc. 

1901 North Roselle 
 Suite 700 
 Schaumburg, Illinois 60195 

USA 
 Attention:
Jeffry Yordon 
 Facsimile No.: 847 908 1601 
 If to WORLDGEN: 
 120 Route 17 North 

P.O. Box 1579 

Paramus, NJ 07653 

USA 
 Attention:
[***] 
 No: [***] 
 or
to such other address as the addressee shall have last furnished in writing to the addresser. 
 16.10 Entire Agreement.
This Agreement, including any exhibits and schedules attached hereto and referenced herein, together with the Quality Agreement entered into pursuant to this Agreement, constitutes the full understanding of the Parties and a complete and exclusive
statement of the terms of their agreement with respect to the subject matter hereof, and no terms, conditions or understandings or agreements purporting to modify or vary the 

  
 16 

 
terms thereof shall be binding unless it is hereafter made in writing and signed by each of the Parties. No modification to this Agreement shall be effected by the acknowledgement or acceptance
of any purchase order or shipping instructions forms or similar documents containing terms or conditions at variance with or in addition to those set forth herein. In the event of a conflict between this Agreement and the exhibits and schedules
hereto, the terms of this Agreement shall control. This Agreement may be amended and supplemented only by a written instrument signed by each of the Parties. 
 16.11 Counterparts; Facsimile Signature Pages. This Agreement may be executed by the Parties by facsimile and in one or more counterparts, each of which shall be deemed an original and all of
which, taken together, shall constitute one and the same instrument. 
 16.12 Currency. Unless otherwise indicated, all
monetary amounts are expressed in this Agreement in United States Dollars ($USD). 
 16.13 Sections and Headings.
The division of this Agreement into Articles, Sections, Subsections, Exhibits and Schedules and the insertion of headings are for the convenience of reference only and shall not affect the interpretation of this Agreement. Unless otherwise
indicated, any reference in this Agreement to a Section or Schedule refers to the specified Section or Schedule to this Agreement. In this Agreement, the terms “this Agreement”, “hereof”, “herein”, “hereunder”
and similar expressions refer to this Agreement and not to any particular part, Section, Schedule or the provision hereof. 

16.14 Singular Terms. Except as otherwise expressly provided herein or unless the context otherwise requires, all references to
the singular shall include the plural and vice versa. 
 SIGNATURE PAGE TO FOLLOW 

  
 17 

 IN WITNESS WHEREOF, this Agreement has been executed as of the date first above written.

  

			
		  	SAGENT PHARMACEUTICALS, INC.
		
		  	By: /s/ Jeffrey
Yordon                                 
		
		  	Name: Jeffrey
Yordon                                
		
		  	Title: CEO                           
                         
		
		  	A.C.S. Dobfar S.p.a.
		
		  	By: /s/ Falciani
Marco                                 
		
		  	Name: Falciani
Marco                                 
		
		  	Title: President                          
                  
		
		  	WORLDGEN LLC
		
		  	By: /s/ Vincent M.
Durate                           
		
		  	Name: Vincent M.
Durate                           
		
		  	Title: Exec. Vice
President                          

  
 18 

 EXHIBIT A 

PRODUCT 
 Cefepime
Hydrochloride 1gram and 2 gram vials for injection. 

  
 19 

 CONFIDENTIAL TREATMENT 
 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. This text has been separately filed with the Securities and Exchange Commission 

 

 EXHIBIT B 

MILESTONE PAYMENT 
 [***],
payable as follows: 
 [***], promptly upon execution of this Agreement; and 
 [***], promptly following the Commercial Launch Date. 

  
 20 

 CONFIDENTIAL TREATMENT 
 [***] Indicates that text has been omitted which is the subject of a confidential treatment request. This text has been separately filed with the Securities and Exchange Commission 

 

 EXHIBIT C 

TRANSFER PRICE 
 Cefepime
Hydrochloride 1 gram: [***]* 
 Cefepime Hydrochloride 2 gram: [***]* 

 
  

	*	The prices set forth herein shall be subject to periodic review and subsequent agreement by the Parties in order to determine changes in the market conditions and/or
manufacturing cost and any reductions related thereto. 

  
 21

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}]]